[unlisted company roadshow] brings many high-quality projects to the investment community

Source: China pharmaceutical innovation promotion association held 5 road shows of unlisted companies at the "Second China Pharmaceutical Innovation and investment conference" on October 29-31, 2017 After the active application in the early stage and careful selection by the Organizing Committee of the conference, it provides a high-end platform for domestic and foreign high-quality innovative enterprises and projects with great development potential to show to the investment community There are 50 non listed companies participating in the roadshow, covering multiple treatment fields and involving the whole pharmaceutical industry The institutions participating in the roadshow include the Institute of medicine of the Chinese Academy of Medical Sciences, Shanghai Institute of medicine of the Chinese Academy of Sciences and other powerful scientific research institutions, such as Xinda biology, lizumab, Qilu pharmaceutical, Rongchang biology, Yasheng pharmaceutical, Hualing pharmaceutical, Geli pharmaceutical, Suzhou Corning Jerry, cutting-edge biology, cornerstone pharmaceutical, Shanghai Zesheng and other well-known innovation and R & D enterprises, as well as Wuhan Heyuan, Suzhou Zejing, Zhejiang Ruishun, Yiteng pharmaceutical, Taizhou Yueyang, xunuo pharmaceutical and other emerging start-up R & D companies, as well as pharmaceutical R & D, information technology and consulting services companies such as telmai biology, Yaodu Jingwei, zero krypton technology, imeda, etc most of these institutions / companies have received major special support This conference has set up a high-end stage for these institutions / companies to demonstrate their R & D key products or advanced technology platform and their expertise in long-term planning and financing needs in the field It has attracted the attention of a large number of s-funded institutions and sent many people to attend the conference At the same time, each unlisted roadshow also invited the chief analysts or experts of domestic well-known investment institutions to make the opening theme report of pharmaceutical investment trend analysis in five unlisted company roadshows, and interpreted the current situation and trend of China's pharmaceutical industry development from the perspective of capital intervention in pharmaceutical innovation Opening report speaker line 1: Li Kaijun, managing partner of Shanghai Lize Investment Management Co., Ltd (left), Yang Yihui, chief analyst of Tianfeng securities (middle), Tian Qiang, chief analyst of CITIC Securities pharmaceutical industry (right) The second line: Wang Min (left), investment partner of Qiming Weichuang venture capital management (Shanghai) Co., Ltd., and Zou Peng (right), deputy general manager of Research Department of China International Finance Co., Ltd (right) are competing for high-quality projects, attracting the attention of many investors, and there are no empty seats in each branch On the spot of the roadshow sub venue of unlisted enterprises, the key innovative drug project of the roadshow of unlisted companies is a collection of the young vaccine products of the Scientific Research Institute of China Academy of Medical Sciences, the small molecule tumor immunotherapeutics and the research and development platform of autoimmune disease treatment drugs of the Pharmaceutical Research Institute of the Chinese Academy of medical sciences are in need of various modes of commercial cooperation Mefurepiride hydrochloride, a new type of PARP inhibitor developed by Shanghai Institute of medicine, Chinese Academy of Sciences, which is easy to penetrate the blood-brain barrier, has obtained the approval of clinical trials and is seeking to transfer and conduct clinical trials Hualing pharmaceutical, a high-quality project of innovative R & D enterprises, has developed a global original new mechanism for the treatment of type 2 diabetes, hms5552, a class 1.1 small molecular glucokinase activator, which is currently in phase III clinical research stage The core anti-virus technology platform of Geli Pharmaceutical Co., Ltd includes three generations of innovative hepatitis C drugs, asc09 anti AIDS class 1 innovative drugs and other products under research Rongchang biological introduced its new biological drug rc-18, which is currently in phase III clinical trials, and rc-48, which is an antibody drug coupling (ADC) innovative drug in phase II clinical trials At present, six products of AXA have entered the phase I-II clinical stage in the United States, Australia and China, and the product pipeline mainly focuses on the key protein inhibitors of apoptosis pathway Xinda biology has a product chain of 13 new drug varieties, covering four major disease fields, including tumor, fundus disease, autoimmune disease and cardiovascular disease Five of them have been selected into the national "major new drug creation" project, and four products have entered the clinical phase III Qilu pharmaceutical develops innovative small molecule and biotechnological drugs (including biological analogues) in the fields of tumor, liver disease, autoimmune system disease and other indications, which are in the preclinical stage III clinical stage respectively Corning Jerry has developed HER-2 bispecific antibody kn026 by using the FC heterodimer platform technology with independent intellectual property rights It is a major new drug creation project in the 13th five year plan and has submitted clinical application to CFDA The advanced biological research and development of ibovetai is the first long-term new drug in the global AIDS treatment field At present, the phase III clinical trial has reached the main end point index in advance, and is expected to be approved for market in 2017 In addition, cs1001, a PD-L1 McAb independently developed by cornerstone pharmaceutical, has been approved for clinical trials The new class I biological product "plant derived recombinant human serum albumin injection" independently developed by Heyuan biology has entered into clinical research There are many unique high-quality projects, including cancer, diabetes, cardiovascular disease, autoimmune disease, gout and other treatment fields The introduction of pharmaceutical innovation information service platform project information technology service companies such as Yaodu Jingwei, zero krypton technology, and aimida also published wonderful reports As the first big data platform to establish one-stop drug research and development services, Yaodu makes massive data visible, readable and available with professional pharmaceutical knowledge and combined with big data through machine learning; zero krypton technology applies real world big data to the whole life cycle of drugs, and is committed to providing big data to assist decision-making, public opinion monitoring and brand building of hospitals, drug equipment research and development, insurance control, and patients Integrated services such as whole process management; based on big data of medical and health industry, through professional data analysis, combined with pharmacoeconomics and market access process, aimida provides a complete set of technical and market solutions for pharmaceutical enterprises by using academic activity platform, and provides technical and policy consulting services for pharmaceutical investment enterprises There are many excellent projects in the unlisted roadshow, which create a bridge for the rapid collision and cooperation between pharmaceutical enterprises and capital After the speech, many reporters were immediately "chased and stopped" by many investment institutions, reflecting the great attention and enthusiasm of the investment community for innovative projects The success of all the unlisted roadshows in this conference also reflects the great effort and great investment of the Organizing Committee in selecting projects and building platforms Some roadshow enterprises / institutions project reporter line 1: Chen Li (left), CEO of Hualing Pharmaceutical Technology (Shanghai) Co., Ltd., Wu JINZI (middle), CEO of Geli Pharmaceutical (Zhejiang) Co., Ltd., and Yang Dajun, chairman and CEO of Yasheng Pharmaceutical (right) Second line: Fang Jianmin (left), general manager and chief scientific officer of Rongchang biopharmaceutical (Yantai) Co., Ltd., Xu Ting (middle), President of Suzhou Kangning Jerry Biotechnology Co., Ltd., Xi Hao (right), chief financial officer of Xinda Biology (Suzhou) Co., Ltd Third line: Chen Xiaoguang (left), Secretary of the Party committee of the Institute of medicine, Chinese Academy of Medical Sciences; Miao Zehong (middle), research leader of Shanghai Institute of medicine, Chinese Academy of Sciences; He Yun, President of the school of medicine, Chongqing University (right)